These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 6891640)
1. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Wieberdink J; Benckhuysen C; Braat RP; van Slooten EA; Olthuis GA Eur J Cancer Clin Oncol; 1982 Oct; 18(10):905-10. PubMed ID: 6891640 [TBL] [Abstract][Full Text] [Related]
2. Dosimetry of cytostatics in hyperthermic regional isolated perfusion. van Os J; Schraffordt Koops H; Oldhoff J Cancer; 1985 Feb; 55(4):698-701. PubMed ID: 3967166 [TBL] [Abstract][Full Text] [Related]
3. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Klaase JM; Kroon BB; van Geel BN; Eggermont AM; Franklin HR; Hart GA Am J Surg; 1994 Jun; 167(6):618-20. PubMed ID: 8209941 [TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. Thompson JF; Gianoutsos MP World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803 [TBL] [Abstract][Full Text] [Related]
5. Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. van de Merwe SA; van den Berg AP; Kroon BB; van den Berge AW; Klaase JM; van der Zee J Int J Hyperthermia; 1993; 9(2):205-17. PubMed ID: 8468505 [TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; Hart AA Surgery; 1994 Jan; 115(1):39-45. PubMed ID: 8284759 [TBL] [Abstract][Full Text] [Related]
7. A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. Byrne DS; McKay AJ; Blackie R; MacKie RM Eur J Cancer; 1996 Nov; 32A(12):2082-7. PubMed ID: 9014749 [TBL] [Abstract][Full Text] [Related]
8. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926 [TBL] [Abstract][Full Text] [Related]
9. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Kroon BB; Van Geel AN; Benckhuijsen C; Wieberdink J Anticancer Res; 1987; 7(3 Pt B):441-2. PubMed ID: 3631900 [TBL] [Abstract][Full Text] [Related]
10. Effect of variation of drug dosage on disease control and regional toxicity in prophylactic perfusion for Stage I extremity melanoma. Mikhail RA; Boddie AW; Ames FC; Zimmerman SO; McBride CM J Surg Oncol; 1984 Dec; 27(4):215-8. PubMed ID: 6503295 [TBL] [Abstract][Full Text] [Related]
11. A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Lejeune FJ; Ghanem GE Cancer Res; 1987 Jan; 47(2):639-43. PubMed ID: 3791248 [TBL] [Abstract][Full Text] [Related]
12. Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; van Dongen JA Melanoma Res; 1994 Mar; 4 Suppl 1():13-6. PubMed ID: 8038589 [TBL] [Abstract][Full Text] [Related]
13. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma]. Kettelhack C; Hohenberger P; Schlag PM Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487 [TBL] [Abstract][Full Text] [Related]
14. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Wu ZY; Smithers BM; Roberts MS Melanoma Res; 1997 Jun; 7(3):252-64. PubMed ID: 9195565 [TBL] [Abstract][Full Text] [Related]
15. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Vrouenraets BC; Eggermont AM; Klaase JM; Van Geel BN; Van Dongen JA; Kroon BB Eur J Surg Oncol; 1994 Dec; 20(6):681-5. PubMed ID: 7995421 [TBL] [Abstract][Full Text] [Related]
16. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Vrouenraets BC; Klaase JM; Kroon BB; van Geel BN; Eggermont AM; Franklin HR Arch Surg; 1995 Jan; 130(1):43-7. PubMed ID: 7802575 [TBL] [Abstract][Full Text] [Related]
17. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor]. Kettelhack C; Hohenberger P; Schlag PM Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810 [TBL] [Abstract][Full Text] [Related]
18. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986 [TBL] [Abstract][Full Text] [Related]
19. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Kroon HM; Moncrieff M; Kam PC; Thompson JF Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289 [TBL] [Abstract][Full Text] [Related]
20. [Technic of isolated perfusion of the extremities. Experience with 171 cases]. Aigner K; Schwemmle K Langenbecks Arch Chir; 1983; 359(2):113-22. PubMed ID: 6681855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]